University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
January 13, 2026

Members attending the meeting: Bieniek, Kevin; Burgin, Tiffani; Chen, Ching-Kang Jason; Chen, Chun-Liang; Dell, Shelbie; Kautz, Tiffany; Martinez-Sobrido, Luis; Mishra, Bibhuti; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Shiio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Rincon, Erica; Melendez, Griselda; Barlett, Emily.

Absent members: Cerecero, Jennifer; Chatterjee, Bandana; Gauduin, Marie Claire; Ginsburg, Brett; Gould, Georgianna; Yeh, Chih-Ko.

1. **Panel Chair Announcement**
   The meeting was called to order at 11:01 a.m. by the IBC Chair, Dr. Yan Xiang.

2. **Confidentiality of Panel Proceedings and Conflict of Interest**
   The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

   Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. **Approval of minutes from the previous meeting**
   The Committee approved the minutes as written from the December 09, 2025, IBC meeting.
   Approved (16 voted to approve, 0 opposed, 0 abstained)

4. **Review of Approved Protocols-** The spreadsheet of FY2026 approved protocols was sent out for review in December 2025.

5. **Old Business –**

6. **Educational Items –** None

7. **Occupational Medicine-** As of January 1, 2026, there were six cases of needlesticks, three of which were by students, and three by UT staff. There were three cases of bloodborne exposure by UT staff members.

8. Other – The SARS-CoV-2 SOP was discussed, and two points were raised that require modifications, and the SOP was approved.

9. Review of EHS Assistant-
Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on February 17, 2026.

Protocols for Review

11. Presentation, Discussion, and Voting on an Initial Protocol:
Protocol ID: 0000018927
Principal Investigator: Li, Hong-Yu; Pharmacology
Title: N/A
Review Type: Full Committee Review
Form Type: Initial

Approved (16 voted to approve, 0 opposed, 0 abstained)

Initial application to work with human cell lines (22RV1, LNCAP, MDA-MB-231, PC3, DU145, MCF-7) at BSL-2 containment. Work with BaF3 mouse cell lines at BSL-1 containment
Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

12. Presentation, Discussion, and Voting on an Amendment Protocol:
Protocol ID: 0000020831
Principal Investigator: Harris, Reuben; Biochemistry & Structural Biology
TITLE: APOBEC mutagenesis in cancer.
NIH-NCI NATIONAL CANCER INSTITUTE - Funding ID# 2P01CA234228-06A1
Review Type: Full Committee Review
Form Type: Amendment

Approved (16 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with Vaccinia virus (mutant), and plasmids (pu19, pcDNA5/TO) at BSL-2+ containment.
Protocol does include the use of recombinant DNA.

This protocol was approved with clarifications.

1. The committee requested additional information on where the strain is obtained from.
2. The committee requested additional information on how the oncologic virus is made and whether it is purchased or made in the lab.
3. The committee requested clarification on which procedures will be used with which human cells.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Transfer of Drug Resistance trait to microorganisms that are not known to acquire that trait naturally, if such acquisition could compromise the ability to control disease agents in humans, veterinary medicine or agriculture. (A drug that is used to treat disease caused by the biological agent under study) (Requires NIH approval) III-A-1-a
Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

13. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 0000021288
Principal Investigator: Gius, David; Radiation Oncology
TITLE: N/A
Review Type: Full Committee Review
Form Type: Renewal

Approved (16 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with replication-defective Lentivirus, human cell lines (HEK293, HEK293T, HELA, MCF-7, T47D, THP-1, MCF-10a, MDA-MB-231, Raw264.7), Sirt3 KO mammary tumors, and vectors (pcDNA3, pCMV, pcDNA, psPAX2, pCMV-VSV-G, pLenti-CMV-MCS-GFP-SV-puro, pLKO.1) at BSL-2 containment. Work E. coli DH5alpha and E. coli STBL3 at BSL-1 containment.

In vivo
Work with human cell lines (MCF-7, T47D, Sirt3 KO) in knock-out and transgenic mice at ABSL-2 containment.
IACUC# 20200075AR
Protocol does include the use of recombinant DNA.

This protocol was approved with clarifications.

1. The committee requested clarification on the titer physical unit of the lentivirus.
2. The committee requested additional information on the different components of the lentivirus virus on whether they are packaged in the lab or purchased.
3. The committee noted that the information provided on the new mouse strains required additional information.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF)II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

14. Presentation, Discussion, and Voting on an Initial Protocol:
Protocol ID: 0000021202
Principal Investigator: Taverna, Josephine; Molecular Medicine
TITLE: AXL-STAT3 targeting Lung Tumor Microenvironments.
NIH- Funding ID# 5R01CA269766-02
CLINICAL TRIAL: V Foundation "AXL-STAT3-PD1 targeting of tumor immune microenvironments ID# T2024-004
Review Type: Full Committee Review
Form Type: Initial

Approved (16 voted to approve, 0 opposed, 0 abstained)

Initial application to work with replication defective lentivirus, human blood, human plasma, human cell lines (293T, A549, HCC1806, HCC-70, BT-549, RD, TC-32, RH-30, JR1, U2OS, HEK293), Cancer cells lines, Breast cancer cell lines, Ewing sarcoma, PDX (patient derived xerograph) and vector (GFP-LC3) at BSL-2 containment. Work with mouse blood at BSL-1 containment.

In vivo
Work with PDX in mice at ABSL-2.
IACUC# IPROTO202500000055, #IPROTO20250000115
Protocol does include the use of recombinant DNA.

This protocol was approved with clarifications.

1. The committee requested additional information on how the PDX cells will be utilized in the lab and in the animals.
2. The committee requested clarification on PBMC samples were sourced from and if they were screened

for bloodborne agents and other infectious agents.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF)II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

15. Presentation, Discussion, and Voting on an Amendment Protocol:
Protocol ID: 0000021229
Principal Investigator: Lin-Smith, Lillian; Molecular Medicine
TITLE: The PAI-1/LRP1 Axis as a Therapeutic Target for Immunosuppression in Endometrial Cancer.
Review Type: Full Committee Review
Form Type: Amendment

Approved (16 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with Human Adenocarcinoma, human cell lines (HEC-1-A, RL95-2), and vectors (GFP-luc, td-Tomato-luc) at BSL-2 containment.

In vivo
Work with human Adenocarcinoma in mice at ABSL-2.
IACUC# 202500000069
Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

Adjourn: The meeting adjourned at 12:16 P.M.

Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio

Dorothy Macias
Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam